Ignite Creation Date:
2024-05-06 @ 4:02 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04857372
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2021-04-20
Brief Title:
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-label Multi-center Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma NF2LATS1LATS2 mutated tumors and tumors with functional YAPTAZ fusions and to identify the maximum tolerated dose andor recommended dose
Detailed Description:
This is a phase I open-label multi-center study of IAG933 as a single agent consisting of a dose escalation part followed by a dose expansion part The escalation part will characterize the safety and tolerability After the determination of the recommended dosemaximum tolerated dose dose expansion will assess the preliminary anti-tumor activity in defined patient populations and further assess the safety and tolerability at RDMTD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None